Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $796.57 Consensus Price Target from Analysts

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given an average recommendation of “Moderate Buy” by the twenty-seven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, eight have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $789.9091.

REGN has been the subject of a number of recent research reports. Bank of America upped their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the company an “underperform” rating in a research note on Wednesday, October 29th. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, November 9th. Morgan Stanley reduced their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Citigroup upped their target price on shares of Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, BMO Capital Markets raised their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research note on Monday, August 4th.

Regeneron Pharmaceuticals Stock Up 1.9%

NASDAQ REGN opened at $694.99 on Friday. Regeneron Pharmaceuticals has a twelve month low of $476.49 and a twelve month high of $803.41. The stock has a market cap of $73.04 billion, a PE ratio of 16.64, a PEG ratio of 2.03 and a beta of 0.31. The firm has a 50-day simple moving average of $596.36 and a 200 day simple moving average of $570.46. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the prior year, the firm posted $12.46 EPS. The company’s revenue for the quarter was up .9% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christine A. Poon sold 6,500 shares of the stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. This trade represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several large investors have recently added to or reduced their stakes in REGN. PGGM Investments lifted its position in shares of Regeneron Pharmaceuticals by 159.7% in the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Founders Capital Management LLC increased its stake in Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after buying an additional 538 shares during the last quarter. Sepio Capital LP increased its stake in Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after buying an additional 842 shares during the last quarter. Generate Investment Management Ltd bought a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $6,300,000. Finally, Bellecapital International Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 32.7% during the 2nd quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after buying an additional 6,283 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.